Put Acute Pain in Its Place

Treat minor strains, sprains, and contusions at the site of injury1

RUNNER DESKTOP RUNNER DESKTOP

NOW AVAILABLE
FLECTOR®
15-Count Box

Also available in a 30-count box

GET SAMPLES »

FLECTOR—the original NSAID topical system1,2

Adheres to intact skin to deliver pain relief where it hurts1

Localized action reduces potential for systemic exposure1

Pain relief onset within 3 to 4 hours3,4

Recommended dose: 1 patch to the most painful area twice daily1*

FLECTOR should not be applied to damaged or non-intact skin1

*Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.1

RX DAW Icon

To ensure your patients receive brand-name FLECTOR, add “dispense as written” (or your state’s legal language) to your prescription.

Apply targeted relief directly to the site of acute pain1*

Potential application sites for FLECTOR1,5

Shoulder Icon

Shoulder

Neck Icon

Neck

Elbow Icon

Elbow

Ankle Icon

Ankle

Foot Icon

Foot

Back Icon

Back

Recommended dose: 1 patch to the most painful area twice daily. Use the lowest effective dosage for the shortest duration consistent with individual treatment goals.1

*Acute pain due to minor strains, sprains, or contusions.1


Explore the possibilities with FLECTOR

This provides information regarding formulation only and is not intended to imply any product comparisons about safety or efficacy. For details, please see the full prescribing information for each product. This is not a complete listing of all approved pain medications.

Nonprescription; product features may vary by formulation.

INDICATIONS AND USAGE

FLECTOR® (diclofenac epolamine) topical system 1.3% is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

INDICATION & IMPORTANT SAFTEY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.

INDICATIONS AND USAGE

FLECTOR® (diclofenac epolamine) topical system 1.3% is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.
  • FLECTOR is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Bleeding, Ulceration, and Perforation

  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

CONTRAINDICATIONS

FLECTOR is contraindicated in the following patients:

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

The most common adverse reactions in FLECTOR and placebo-treated adult patients were pruritus (5% and 8%, respectively) and nausea (3% and 2%, respectively). The most common adverse reactions in FLECTOR treated pediatric patients were headache (9%) and application site pruritus (7%).

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

For Full Prescribing Information, including BOXED WARNING, click here.